These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 9834825)

  • 1. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
    Bangerter M; Moog F; Buchmann I; Kotzerke J; Griesshammer M; Hafner M; Elsner K; Frickhofen N; Reske SN; Bergmann L
    Ann Oncol; 1998 Oct; 9(10):1117-22. PubMed ID: 9834825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil.
    Cerci JJ; Pracchia LF; Soares Junior J; Linardi Cda C; Meneghetti JC; Buccheri V
    Clinics (Sao Paulo); 2009; 64(6):491-8. PubMed ID: 19578651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
    Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
    Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution.
    Partridge S; Timothy A; O'Doherty MJ; Hain SF; Rankin S; Mikhaeel G
    Ann Oncol; 2000 Oct; 11(10):1273-9. PubMed ID: 11106116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Belhocine T; Hustinx R; Rigo P; Fillet G
    Ann Oncol; 2003 Jan; 14(1):123-30. PubMed ID: 12488304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
    Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease.
    Weihrauch MR; Re D; Bischoff S; Dietlein M; Scheidhauer K; Krug B; Textoris F; Ansén S; Franklin J; Bohlen H; Wolf J; Schicha H; Diehl V; Tesch H
    Ann Hematol; 2002 Jan; 81(1):20-5. PubMed ID: 11807631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
    Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
    J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease.
    Kabickova E; Sumerauer D; Cumlivska E; Drahokoupilova E; Nekolna M; Chanova M; Hladikova M; Kodet R; Belohlavek O
    Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1025-31. PubMed ID: 16565847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
    Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
    Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.
    Purz S; Mauz-Körholz C; Körholz D; Hasenclever D; Krausse A; Sorge I; Ruschke K; Stiefel M; Amthauer H; Schober O; Kranert WT; Weber WA; Haberkorn U; Hundsdörfer P; Ehlert K; Becker M; Rössler J; Kulozik AE; Sabri O; Kluge R
    J Clin Oncol; 2011 Sep; 29(26):3523-8. PubMed ID: 21825262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
    Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ
    Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography.
    Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S
    Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staging in childhood lymphoma: differences between FDG-PET and CT.
    Hermann S; Wormanns D; Pixberg M; Hunold A; Heindel W; Jürgens H; Schober O; Franzius C
    Nuklearmedizin; 2005 Feb; 44(1):1-7. PubMed ID: 15711722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
    Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P
    Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
    Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
    Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
    Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
    J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.